Special 12/2012

  • BIO-Regions in the European Union

    In an era of tight purse-strings when it comes to collecting capital for long-term projects like drug development, the concentration of know-how in a biotech cluster, incubator or meta-cluster offers bio­tech companies many advantages. Access to a common infrastructure and networks, better visibility for potential corporate and VC investors, and improved access to public funding are only a few of them. Well­­-established biotech hubs also exert an irresistible appeal to national and EU policymakers. They of course are seeking to create high-paying jobs, attract new companies as well as investors and stimulate the socioeconomic growth of entire regions (see p. 38). In this special, EuroBio­techNews presents some of the strategies that European bio-incubators are implementing in their quests to become the next major global hub.

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/spezial/2012/12.html

Kurszettel

Alle Kurse

TOP

  • BIOFRONTERA2.44 EUR10.91%
  • WILEX2.19 EUR4.29%
  • PAION3.28 EUR1.86%

FLOP

  • SANTHERA83.00 CHF-4.54%
  • EVOLVA1.19 CHF-4.03%
  • BB BIOTECH149.65 EUR-2.95%

TOP

  • PAION3.28 EUR36.1%
  • CO.DON3.05 EUR24.0%
  • FORMYCON8.17 EUR15.9%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.05 EUR-18.0%
  • 4SC1.01 EUR-14.4%

TOP

  • SANTHERA83.00 CHF2044.7%
  • PAION3.28 EUR245.3%
  • CO.DON3.05 EUR214.4%

FLOP

  • CYTOS0.18 CHF-95.3%
  • 4SC1.01 EUR-46.0%
  • MOLOGEN6.64 EUR-44.2%

No liability assumed, Date: 01.10.2014